OncoMatch/Clinical Trials/NCT05827796
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
Is NCT05827796 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including IN10018 and Albumin-Bound Paclitaxel for pancreatic cancer.
Treatment: IN10018 · Albumin-Bound Paclitaxel · Gemcitabine · KN046 — This study is a multicenter, open-label, single-arm, phase Ib/II clinical study comprising two phases: dose confirmation phase and dose expansion phase. The objective of the dose confirmation phase is to determine the recommended Phase II dose (RP2D) of IN10018+ standard chemotherapy (albumin-bound paclitaxel + gemcitabine) and IN10018 + KN046 + standard chemotherapy in subjects with advanced pancreatic cancer. The dose expansion phase will further explore the antitumor activities and safety of combination therapy in subjects with advanced pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Excluded: BRCA1 mutation
Excluded: BRCA2 mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anticancer therapy
Has received prior systemic anticancer therapy including chemotherapy, targeted therapy, immunotherapy, unmarketed investigational drugs or therapy within 28 days prior to the first dose of study treatment
Cannot have received: anti-PD-1 therapy
Previous anti-programmed death 1(PD-1), anti-programmed death-ligand 1 (PD-L1), or anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody therapy, or any other antibody or drug that specifically targets T-cell co-stimulation or checkpoint pathways, or prior treatment with focal adhesion kinase (FAK) inhibitors
Cannot have received: anti-PD-L1 therapy
Previous anti-programmed death 1(PD-1), anti-programmed death-ligand 1 (PD-L1), or anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody therapy, or any other antibody or drug that specifically targets T-cell co-stimulation or checkpoint pathways, or prior treatment with focal adhesion kinase (FAK) inhibitors
Cannot have received: anti-CTLA-4 therapy
Previous anti-programmed death 1(PD-1), anti-programmed death-ligand 1 (PD-L1), or anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody therapy, or any other antibody or drug that specifically targets T-cell co-stimulation or checkpoint pathways, or prior treatment with focal adhesion kinase (FAK) inhibitors
Cannot have received: focal adhesion kinase inhibitor
prior treatment with focal adhesion kinase (FAK) inhibitors
Cannot have received: systemic chemotherapy
No previous systemic treatment for unresectable, locally advanced, or metastatic pancreatic cancer
Cannot have received: radical radiotherapy
Exception: palliative radiotherapy with a local standardized dose within 2 weeks prior to the first dose of study treatment
Has received radical radiotherapy within 3 months prior to the first dose of study treatment. Subjects who have received palliative radiotherapy with a local standardized dose within 2 weeks prior to the first dose of study treatment.
Cannot have received: allogeneic hematopoietic stem cell transplantation
Has received previous allogeneic hematopoietic stem cell transplantation or organ transplantation
Cannot have received: organ transplantation
Has received previous allogeneic hematopoietic stem cell transplantation or organ transplantation
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify